XTANT MEDICAL HOLDINGS, INC. Financials Xtant Medical Holdings, Inc.
Equities
XTNT
US98420P3082
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8946 USD | -3.81% |
|
-1.58% | -20.83% |
| Apr. 30 | Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds | CI |
| Apr. 01 | Xtant Medical Files $150 Million Mixed Shelf; Shares Fall | MT |
Valuation
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 21.06 | 71.72 | 147 | 116.5 | - | - |
| Enterprise Value (EV) 1 | 21.06 | 71.72 | 147 | 116.5 | 116.5 | 116.5 |
| P/E ratio | -2.58 x | -7.33 x | 113 x | -14.9 x | -179 x | 44.7 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.33 x | - | 1.61 x | 1.01 x | 0.89 x | 0.74 x |
| EV / Revenue | 0.33 x | - | 1.61 x | 1.01 x | 0.89 x | 0.74 x |
| EV / EBITDA | 5.44 x | - | 142 x | 23.3 x | 9.71 x | - |
| EV / FCF | - | - | -13.4 x | -29.1 x | 25.9 x | - |
| FCF Yield | - | - | -7.46% | -3.43% | 3.86% | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 13,162 | 108,659 | 130,110 | 130,217 | - | - |
| Reference price 2 | 1.600 | 0.6600 | 1.130 | 0.8946 | 0.8946 | 0.8946 |
| Announcement Date | 3/5/20 | 3/7/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 64.68 | - | 91.3 | 115 | 130.4 | 157 |
| EBITDA 1 | 3.869 | - | 1.038 | 5 | 12 | - |
| EBIT 1 | -2.253 | - | -10.16 | -6.85 | 0.5 | 5 |
| Operating Margin | -3.48% | - | -11.13% | -5.96% | 0.38% | 3.18% |
| Earnings before Tax (EBT) 1 | -8.123 | - | -1.037 | -8.3 | -0.9 | 5 |
| Net income 1 | -8.221 | -8.485 | 0.66 | -8.3 | -0.9 | 4 |
| Net margin | -12.71% | - | 0.72% | -7.22% | -0.69% | 2.55% |
| EPS 2 | -0.6200 | -0.0900 | 0.0100 | -0.0600 | -0.005000 | 0.0200 |
| Free Cash Flow 1 | - | - | -10.97 | -4 | 4.5 | - |
| FCF margin | - | - | -12.02% | -3.48% | 3.45% | - |
| FCF Conversion (EBITDA) | - | - | - | - | 37.5% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 3/7/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 17.94 | 20.23 | 25.02 | 28.11 | 25.77 | 27.91 | 29.07 | 32.24 | 28.94 |
| EBITDA 1 | -0.29 | 0.101 | 0.452 | 0.761 | 0.377 | 1.035 | 1.692 | 1.915 | 2.293 |
| EBIT 1 | -1.576 | -1.391 | -3.385 | -3.806 | -1.95 | -1.6 | -1.5 | -1.85 | -0.35 |
| Operating Margin | -8.78% | -6.88% | -13.53% | -13.54% | -7.57% | -5.73% | -5.16% | -5.74% | -1.21% |
| Earnings before Tax (EBT) 1 | -2.065 | -2.177 | 6.931 | -3.726 | -2.3 | -1.95 | -1.85 | -2.2 | -0.7 |
| Net income 1 | -2.078 | -2.19 | 9.231 | -4.303 | -2.3 | -1.95 | -1.85 | -2.2 | -0.7 |
| Net margin | -11.58% | -10.82% | 36.9% | -15.31% | -8.93% | -6.99% | -6.36% | -6.82% | -2.42% |
| EPS 2 | -0.0200 | -0.0200 | 0.0700 | -0.0300 | -0.0150 | -0.0150 | -0.0100 | -0.0150 | -0.005000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/4/23 | 8/1/23 | 11/9/23 | 4/1/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -11 | -4 | 4.5 | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | 1.46 | 3 | 2 | - |
| Capex / Sales | - | - | 1.59% | 2.61% | 1.53% | - |
| Announcement Date | 3/5/20 | 3/7/23 | 4/1/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.8946
USD
Average target price
1.925
USD
Spread / Average Target
+115.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.83% | 116M | |
| +12.37% | 128B | |
| -5.97% | 10.69B | |
| +2.17% | 8.93B | |
| +18.79% | 7.32B | |
| +20.77% | 4.82B | |
| +6.97% | 3.4B | |
| -1.41% | 3.03B | |
| -5.07% | 2.23B | |
| -4.22% | 2.13B |
- Stock Market
- Equities
- XTNT Stock
- Financials Xtant Medical Holdings, Inc.
